Sino Medical Sciences Technology Inc. (688108.SS)
CNY 10.24
(-0.49%)
CNY 10.24
(-0.49%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 3.31 Million CNY | 102.37% |
| 2022 | -139.79 Million CNY | -60.98% |
| 2021 | -95.49 Million CNY | -261.81% |
| 2020 | 50.2 Million CNY | -59.37% |
| 2019 | 142.71 Million CNY | 4.42% |
| 2018 | 123.2 Million CNY | 26.45% |
| 2017 | 99.32 Million CNY | 73.99% |
| 2016 | 52.99 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -10.6 Million CNY | -134.73% |
| 2024 Q1 | 6.48 Million CNY | -81.53% |
| 2024 Q2 | 25.87 Million CNY | 950.07% |
| 2023 Q4 | -11.59 Million CNY | 0.31% |
| 2023 Q2 | -11.37 Million CNY | 54.32% |
| 2023 FY | - CNY | 102.37% |
| 2023 Q3 | -11.63 Million CNY | -2.27% |
| 2023 Q1 | -24.89 Million CNY | 62.58% |
| 2022 Q3 | -45.34 Million CNY | 16.5% |
| 2022 FY | - CNY | -60.98% |
| 2022 Q4 | -66.54 Million CNY | -46.75% |
| 2022 Q2 | -54.3 Million CNY | -47.67% |
| 2022 Q1 | -36.77 Million CNY | -48.24% |
| 2021 Q3 | -34.87 Million CNY | 23.3% |
| 2021 Q2 | -45.47 Million CNY | 3.44% |
| 2021 Q4 | -24.8 Million CNY | 28.87% |
| 2021 FY | - CNY | -261.81% |
| 2021 Q1 | -47.09 Million CNY | -46.29% |
| 2020 FY | - CNY | -59.37% |
| 2020 Q4 | -32.18 Million CNY | -330.11% |
| 2020 Q3 | 13.98 Million CNY | -46.47% |
| 2020 Q2 | 26.13 Million CNY | 251.56% |
| 2020 Q1 | 7.43 Million CNY | -73.62% |
| 2019 FY | - CNY | 4.42% |
| 2019 Q2 | 27.95 Million CNY | 3.38% |
| 2019 Q1 | 27.03 Million CNY | -8.61% |
| 2019 Q4 | 28.17 Million CNY | 35.1% |
| 2019 Q3 | 20.85 Million CNY | -25.4% |
| 2018 Q4 | 29.58 Million CNY | 0.0% |
| 2018 Q1 | 92.75 Million CNY | 0.0% |
| 2018 FY | - CNY | 26.45% |
| 2017 FY | - CNY | 73.99% |
| 2016 FY | - CNY | 0.0% |